Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946031 | 0.87 | MAOB (0.64) | MAOBKDM4ETSHRSPHK1MAOA | |
| SCHEMBL684282 | 0.83 | MAOB (0.62) | MAOBKDM4ETSHRMAOABCHE | |
| SCHEMBL9946057 | 0.83 | MAOB (0.60) | MAOBKDM4ETSHRMAOABCHE | |
| SCHEMBL9946090 | 0.81 | PARP10 (0.55) | MAOBKDM4EMAOAPARP10ALDH1A1 | |
| SCHEMBL15340853 | 0.79 | MAOB (0.65) | MAOBKDM4ETSHRSPHK1MAOA | |
| Formaldehyde SCHEMBL27575662 | 0.79 | KMT2A (0.58) | MAOBMAOABCHESMN1; SMN2SGMS2 | |
| SCHEMBL15340870 | 0.79 | NPC1 (0.58) | MAOBKDM4ETSHRSPHK1BCHE | |
| SCHEMBL15340871 | 0.78 | MAOB (0.58) | MAOBMAOA | |
| SCHEMBL18253179 | 0.78 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL26378372 | 0.78 | MAOB (0.59) | MAOBKDM4ETSHRSPHK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885KDM4E 4270/4885TSHR 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.